ClinicalTrials.gg
RecruitingNCT03941574Updated Oct 28, 2022

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

A Phase 2 interventional study of HLX10 in MSI-H Solid Malignant Tumor, sponsored by Shanghai Henlius Biotech. Recruiting at 33 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

It is a single-arm, open-label, multicenter, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 monotherapy for the treatment of patients with unresectable or metastatic MSI-H or dMMR solid tumors who have progressed or intolerable after standard therapy.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria. The enrolled subjects will receive an intravenous infusion of HLX10 (3 mg/kg) once every 2 weeks until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent or other reasons as specified in the protocol, or up to the longest treatment duration-2 years (52 dosing periods) (whichever occurs earlier).

02

Conditions studied

  • MSI-H Solid Malignant Tumor
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet all of the following criteria are allowed to be enrolled into this study:

    • Volunteer to participate in this clinical study; completely understand and know this study as well as sign the form (ICF); be willing to follow and be able to complete all study procedures;
    • Age ≥ 18 years and ≤ 75 years when ICF is signed;
    • Patients with unresectable or MSI-H or dMMR malignant solid tumors which are histopathologically or/and confirmed by the central laboratory or study sites;
    • Patients who have disease progression or intolerable reactions after the currently available standard anti-cancer treatment previously received;
    • The interval between the end of previous systemic anti-tumor treatment and the first dosing of if this study must be ≥ 2 weeks. In addition, treatment-related AEs recover to v4.03 ≤ grade 1 (excluding grade 2 alopecia).
    • There is at least one assessed by IRRC according to the requirements of version 1.1 (Appendix 1).

Note: measurable lesions cannot be selected from the previous radiotherapy sites. If the target lesion of the previous radiotherapy sites is the only one available lesion, the investigator is required to provide imaging data before and after significant progression of such lesion.

  • Subjects must provide tumor tissues and blood samples for the determination of MSI, tumor mutational burden (TMB), expression level (if the test results of the above parameters by the central laboratory specified by this study are available, the subjects are allowed not to receive repeated tests).

Note: it is recommended to provide formalin fixed tumor tissue samples collected from non-radiotherapy sites within 6 months prior to the first dosing of product, paraffin embedded tumor samples (preferred), or formalin fixed paraffin embedded tumor samples or unstained newly sliced serial sections (glass slides). Moreover, the corresponding pathological reports of the above samples must also be provided. Freshly collected samples, excision, core needle , resection, incision, punching or forceps biopsies are within the acceptable range (newly-obtained tissues preferred). The aspiration samples (i.e., lack of complete tissue structure and only cell suspension and/or cell smears are provided), brushing samples, cell precipitation samples from pleural or peritoneal effusion are not acceptable. The requirements for tissue samples are provided in laboratory operating manual in detail.

  • performance status score (Appendix II) of 0 or 1 within 7 days before the first dose of invetigational product;
  • ≥12 weeks;
  • Negative ; patients with positive HBsAg or HBcAb test results can be enrolled only if Hepatitis B virus (HBV) DNA test results are negative.

    11.Negative antibody; patients with positive HCV antibody or HCV-RNA test results can be enrolled only if and AST are CTCAE v4.03 ≤ grade 1 (i.e., ≤ 3×); subjects concurrently infected with hepatitis B and hepatitis C are excluded.

  • Normal function of main organs, and the following criteria are met (within the 14 days before the first injection of investigational product, patients have not received the treatment with blood transfusion, albumin, recombinant human thrombopoietin or colony stimulating factor (CSF)):
  • Female subjects must meet the following criteria:

    ① Menopause (defined as no menstruation for at least one year, and no other confirmed reasons other than menopause), or② Received surgical sterilization (ovariectomy and/or hysterectomy), or③ Subjects who are able to bear or father a child must meet the following criteria:

  • Serum pregnancy test must be negative within 7 days before the first dosing, and
  • Agree to use methods with an annual failure rate of \< 1% or maintain sexual abstinence (avoid heterosexual intercourse) (from the signing of informed consent form to at least 120 days after the last dose of investigational product) (contraceptive methods with an annual failure rate of \< 1% include bilateral tubal ligation, male sterilization, correct use of hormonal contraceptives which may inhibit ovulation, hormone-releasing intrauterine device and copper intrauterine device), and
  • Breast-feeding is not allowed.
  • Male subjects should meet the criteria below: agree to maintain sexual abstinence (avoid heterosexual intercourse) or use contraceptive methods, with requirements detailed below: if the partners of male subjects have or become pregnant, male subjects must maintain sexual abstinence or use condoms to prevent drug exposure to embryos during administration period of investigational product and within at least 120 days after after the last dose of investigational product. The reliability of sexual abstinence should be evaluated based on the duration of clinical studies, preference of the subjects and daily life style. Regular sexual abstinence (e.g., calendar days, ovulation period, basal body temperature or post-ovulation period contraceptive methods) and coitus interruptus are disqualified contraceptive methods.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not allowed to be enrolled in this study:

    • Subjects who plan to undergo or previously underwent organ or bone marrow transplantation.
    • Uncontrollable pleural effusion, pericardial effusion or ascites after appropriate intervention measures.
    • Subjects with known or screening test-confirmed active central nervous system (CNS) and/or carcinomatous meningitis; However, the following subjects are allowed to be enrolled: 1. subjects with asymptomatic (i.e. without progressive central nervous system symptoms caused by brain metastatic lesions, without the requirement of treatment, and lesion size ≤1.5cm) are allowed to participate in this study, however, it is necessary to perform regular brain imaging tests for disease sites. 2. subjects with brain metastasis after treatment, and brain metastatic lesions are stable for at least 1 month, without evidence of new or expanded brain metastasis, and steroids are discontinued 3 days prior to the first dose of the product. Stable brain metastasis in this definition should be confirmed before the first dose of the investigational product.
    • Subjects with spinal cord compression which cannot be radically treated through surgery and/or radiotherapy, or subjects previously diagnosed with spinal cord compression with no post-treatment clinical evidence showing stable disease ≥ 1 week before the first dose of the investigational product.
    • Imaging test results show definit tumor invasion of thoracic great vessels.
    • Occurrence of myocardial ischemia above grade Ⅱ , or myocardial infarction, unstable angina pectoris, inadequately controlled arrhythmia (including ≥ 450 ms for males, and ≥ 470 ms for females) within half a year before the first dose of the investigational product (QTc interval is calculated based on Fridericia formula).
    • Grade Ⅲ or Ⅳ cardiac dysfunction based on (NYHA) Functional Classification (appendix Ⅲ) or echocardiography test showing (LVEF) \< 50%.
    • Presence of peripheral neuropathy with v4.03 ≥ grade 2.
    • Infection with (HIV).
    • Presence of active pulmonary tuberculosis.
    • Previously or currently suffering from interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, seriously injured lung function and other conditions which may interfere with the detection and treatment of suspected drug-related pulmonary toxicity.
    • Presence of know active or suspected diseases; Patients who have stable status and require no treatment with systemic therapies are allowed to be enrolled.
    • Treatment with within 28 days before the first administration of investigational product.
    • Subjects requiring treatment with systemic corticosteroids (> 10 mg/day prednisone or equivalent dose of similar drugs) or other immunosuppressive therapies within 14 days before the first administration of investigational product or during the study period; However, the following conditions are allowed to be enrolled: in the event of no active autoimmune diseases, inhalation or topical use of steroids or adrenaline alternative treatment of effective dose of prednisone ≤ 10 mg/day are allowed.
    • Presence of any active infection requiring systemic anti-infection treatment within 14 days before the first administration of investigational product.
    • Subjects who have received major surgery within 28 days before the first administration of investigational product, by "major surgery", it meant that the patient needs at least three weeks to recover following the surgery before being able to receive the study treatment. Enrollment through tumor puncture or lymph node is allowed.
    • Received radical radiotherapy within 3 months before the first administration of investigational product.

Note: palliative radiotherapies for bones or superficial lesions are acceptable. The course of treatment should be in accordance with the local standard and has ended 14 days before the first administration. Radiotherapy covering more than 30% of the bone marrow area is not allowed within 28 days prior to the first dose.

  • Other anti-tumor treatments such as chemotherapy, targeted therapy or radiotherapy (excluding palliative radiotherapy) may be received during the study period.
  • Previously received treatment with any T cells costimulation or immune checkpoint, including but not limited to cytotoxic T lymphocyte-associated antigen-4 () inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other targeted T cells drugs.
  • Subjects are participating in other clinical studies, or the time interval between the initiation of treatment planned in this study and end of investigational product treatment in the previous clinical study is less than 14 days.
  • Known serious history to any monoclonal antibody or the of investigational product.
  • Pregnant or lactating women.
  • Known history of abuse of psychotropic drugs or drug addiction; Subjects who have stopped drinking are allowed to be enrolled.
  • The subjects have other factors which may cause premature termination of this study at the discretion of the investigators.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    HLX10

    Drug: HLX10

Interventions

  • DrugHLX10

    HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)

    Time frame: up to 2 years

Secondary outcomes

  1. ORR

    Objective response rate (assessed by the investigators based on the RECIST Version 1.1)

    Time frame: up to 2 years

  2. ORR

    Objective response rate (assessed by independent radiological review committee (IRRC) based on the iRECIST)

    Time frame: up to 2 years

  3. 6-month OS rate

    6-month overall survival rate

    Time frame: from the date of first dose unitl the date of 6-month

  4. OS

    Overall survival (OS)

    Time frame: from the date of first dose unitl the date of death from any cause,assessed up to 2 years

  5. 6-month PFS rate

    6-month progression-free survival (PFS) rate

    Time frame: the proportion of subjects who have time interval over 6 months between the first dose and disease progression or death

  6. PFS

    Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1, iRECIST)

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

  7. PFS

    Progression-free survival (assessed by the investigators based on RECIST v1.1)

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

  8. DOR DOR

    Duration of response

    Time frame: from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years

07

Study locations

33 of 33 sites recruiting
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Recruiting
    • Zhendong Chen · Contact
  • Peking University International Hospital
    Beijing, Beijing 102206, China
    Recruiting
    • Jun Liang · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400042, China
    Recruiting
    • Tao Zhang · Contact
  • the 900th Hospital of Joint Logistic Support Force
    Fuzhou, Fujian 35002, China
    Recruiting
    • Xi Chen · Contact
  • Zhongnan Hospital of Wuhan University
    Wuhan, Fujian 430062, China
    Recruiting
    • Fuxiang Zhou · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Recruiting
    • Huangyang Ye · Contact
  • First People's Hospital of Fushan
    Fushan, Guangdong 528010, China
    Recruiting
    • Wei Wang · Contact
  • The First Affiliated Hospital and Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510075, China
    Recruiting
    • Shirong Cai · Contact
  • The First Affiliated Hospital (School of Clinical Medicine), Guangdong Pharmaceutical University
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Xicheng Wang · Contact
  • Affiliated Cancer Hospital & Institute, Guangzhou Medical University
    Guangzhou, Guangdong 510095, China
    Recruiting
    • Chuan Jin · Contact
  • the Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Yanhong Deng · Contact
  • Affiliated Hospital of Guangdong Medical University
    Zhenjiang, Guangdong 510180, China
    Recruiting
    • Zhong Xie · Contact
  • Zhongshan city People's Hospital
    Zhongshan, Guangdong 528404, China
    Recruiting
    • Jianjun Xiao · Contact
  • The Fifth Affiliated Hospital, Sun Yat-sen University
    Zhuhai, Guangdong 519000, China
    Recruiting
    • Hongyu Zhang · Contact
  • The People's Hospital of Guangxi Zhuangzu Autonomous Region
    Nanning, Guangxi 530016, China
    Recruiting
    • Kehe Chen · Contact
  • Fourth Hospital of Hebei Medical University,
    Shijia Zhuang, Hebei 050011, China
    Recruiting
    • Da Jiang · Contact
  • Harbin Medical University Cancer Hospital,
    Harbin, Heilongjiang 150040, China
    Recruiting
    • Yuxian Bai · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Qingxia Fan · Contact
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 200065, China
    Recruiting
    • Xianglin Yuan · Contact
  • The Third Xiangya Hospital, Central South University
    Changsha, Hunan 410013, China
    Recruiting
    • Peiguo Cao · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
    Recruiting
    • Xianli Yin · Contact
  • Qinhuai Medical District, General Hospital of the eastern theater of the Chinese people's Liberation Army
    Nanjing, Jiangsu 210002, China
    Recruiting
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
    Recruiting
    • Yang Zhang · Contact
  • Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
    Recruiting
    • Jingdong Zhang · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Xiuwen Wang · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Changzheng Li · Contact
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
    Recruiting
    • Jin Li · Contact
  • Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China
    Chengdu, Sichuan 610041, China
    Recruiting
    • Yongdong Jin · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Qing Zhu · Contact
  • Tianjin Medical University Cancer Institue and Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
    • Xiubao Ren · Contact
  • Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center
    Kunming, Yunnan 650118, China
    Recruiting
    • Yunfeng Li · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Haijun Zhong · Contact
  • Taizhou first people's Hospital
    Taizhou, Zhejiang 318020, China
    Recruiting
    • Lili Chen · Contact
08

References and documents

Publications

  • Shukui Qin, Jin Li, Haijun Zhong, et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, 2566-2566
  • Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, Fan Q, Chen K, Cao P, Xiao J, Jiang D, Zhang T, Zhang H, Wang X, Wang W, Han L, Wang Q, Zhu J; Serplulimab-MSI-H Investigators. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022 Dec;127(12):2241-2248. doi: 10.1038/s41416-022-02001-3. Epub 2022 Oct 19. Erratum In: Br J Cancer. 2022 Dec;127(12):2249. doi: 10.1038/s41416-022-02043-7. PubMed 36261583 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for May 2024, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 8, 2019
StartActual
Jul 15, 2019
Primary completionEst.
May 30, 2024
CompletionEst.
Jun 30, 2026
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03941574
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Jul 15, 2019
Primary completion
May 30, 2024 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Oct 28, 2022

Study contacts

ShuKui Qin
Contact
luolinhua0513@163.com
86-025-80864362

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion